GRCE (Grace Therapeutics) Forward P/E Multiple

Graphic logo of Grace Therapeutics, Inc. (GRCE)

Demand for rare disease therapies remains insulated from macroeconomic volatility, as evidenced by the forward P/E history of Grace Therapeutics, Inc. (GRCE). The value 0.00 describes the current status of the metric. FDA orphan drug status protects Grace Therapeutics, Inc. (GRCE) from price dumping. However, business success depends on clinical trial results and strict cost control of the R&D pipeline until the company achieves stable profitability.

GRCE - Grace Therapeutics, Inc. Projected Price to Earnings over the range 10/29/2024 - 11/16/2026

Financial and market metric breakdowns for Grace Therapeutics (GRCE)

- stock value and consensus price forecast:
- business market valuation indicators:
Summary company analysis:Grace Therapeutics, Inc.
Product sample of gracetx.com

Grace Therapeutics, Inc. (GRCE) is developing a closed ecosystem for the therapy of rare CNS pathologies, protected by FDA orphan drug status. By analyzing the company's consensus P/E forecast, an investor assesses the ratio of the current price to expected earnings, which, under tight Fed policy, determines the business's ability to monetize innovations; meanwhile, low indicator values signal that the asset is undervalued, while extreme peaks indicate correction risks.

Direct competitors

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Omeros Corporation (OMER)|Neurogene Inc. - Price to Future Earnings Ratio|acimmune.com - Projected Price to Earnings|Forward P/E Multiple Voyager Therapeutics Inc VYGR|NMRA - Future Price to Earnings|Forward Price to Earnings Multiple Scilex Holding Company (SCLX)|Tevogen Bio Holdings (TVGN) - Future Price to Earnings|Price to Future Earnings Ratio ACOG|Future Price to Earnings Cognition Therapeutics, Inc.|Inhibikase Therapeutics, Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings SAVA (Cassava)|Market Cap to Projected Earnings Assertio Therapeutics|Coya Therapeutics, Inc. - Projected Price to Earnings|Market Cap to Future Earnings Ratio VTGN (VistaGen Therapeutics Inc)|Ovid Therapeutics Inc - Forward P/E Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Projected Price to Earnings|CRVO (CervoMed, Inc.) - Projected Price to Earnings|Projected Price to Earnings Alterity Therapeutics Ltd|Future Price to Earnings Clene Inc.|PepGen Inc. - Price to Expected Earnings Ratio|Projected Price to Earnings JUNS (Jupiter Neurosciences Inc)|Future Price to Earnings RLMD (Relmada Therapeutics Inc)|Annovis Bio Inc - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)